GSK plc (G1SK34) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GSK plc (G1SK34) has a cash flow conversion efficiency ratio of 0.473x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (R$7.74 Billion) by net assets (R$16.38 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
GSK plc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how GSK plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
GSK plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GSK plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Enbridge Inc
NYSE:ENB
|
0.047x |
|
Capital One Financial Corporation
NYSE:COF
|
0.069x |
|
China Life Insurance Co Ltd A
SHG:601628
|
0.225x |
|
Banco Bilbao Vizcaya Argentaria SA
MC:BBVA
|
0.278x |
|
Arm Holdings plc
F:O9T
|
0.066x |
|
Bharti Airtel Limited
NSE:BHARTIARTL
|
0.177x |
|
Corning Incorporated
NYSE:GLW
|
0.085x |
|
UniCredit SpA
F:CRIN
|
N/A |
Annual Cash Flow Conversion Efficiency for GSK plc (2018–2024)
The table below shows the annual cash flow conversion efficiency of GSK plc from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | R$13.09 Billion | R$6.55 Billion | 0.501x | -5.32% |
| 2023-12-31 | R$12.79 Billion | R$6.77 Billion | 0.529x | -24.28% |
| 2022-12-31 | R$10.60 Billion | R$7.40 Billion | 0.699x | +87.47% |
| 2021-12-31 | R$21.34 Billion | R$7.95 Billion | 0.373x | -8.15% |
| 2020-12-31 | R$20.81 Billion | R$8.44 Billion | 0.406x | -7.15% |
| 2019-12-31 | R$18.36 Billion | R$8.02 Billion | 0.437x | -80.95% |
| 2018-12-31 | R$3.67 Billion | R$8.42 Billion | 2.293x | -- |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more